90 related articles for article (PubMed ID: 28176139)
1. Lower prostate cancer risk in Swedish men with the androgen receptor E213 A-allele.
Bentmar Holgersson M; Ruhayel Y; Karlsson M; Giwercman A; Bjartell A; Ohlsson C; Mellström D; Ljunggren Ö; Haghsheno MA; Damber JE; Lundberg Giwercman Y
Cancer Causes Control; 2017 Mar; 28(3):227-233. PubMed ID: 28176139
[TBL] [Abstract][Full Text] [Related]
2. Genetic Susceptibility to Prostate Cancer: Prostate-specific Antigen and its Interaction with the Androgen Receptor (United States).
Sieh W; Edwards KL; Fitzpatrick AL; Srinouanprachanh SL; Farin FM; Monks SA; Kronmal RA; Eaton DL
Cancer Causes Control; 2006 Mar; 17(2):187-97. PubMed ID: 16425097
[TBL] [Abstract][Full Text] [Related]
3. Germ-line genetic variation in the key androgen-regulating genes androgen receptor, cytochrome P450, and steroid-5-alpha-reductase type 2 is important for prostate cancer development.
Lindström S; Wiklund F; Adami HO; Bälter KA; Adolfsson J; Grönberg H
Cancer Res; 2006 Nov; 66(22):11077-83. PubMed ID: 17108148
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms in the androgen receptor and the prostate-specific antigen genes and prostate cancer risk.
Salinas CA; Austin MA; Ostrander EO; Stanford JL
Prostate; 2005 Sep; 65(1):58-65. PubMed ID: 15810021
[TBL] [Abstract][Full Text] [Related]
5. Suicide risk in men with prostate-specific antigen-detected early prostate cancer: a nationwide population-based cohort study from PCBaSe Sweden.
Bill-Axelson A; Garmo H; Lambe M; Bratt O; Adolfsson J; Nyberg U; Steineck G; Stattin P
Eur Urol; 2010 Mar; 57(3):390-5. PubMed ID: 19914773
[TBL] [Abstract][Full Text] [Related]
6. Susceptibility to prostate cancer: interaction between genotypes at the androgen receptor and prostate-specific antigen loci.
Xue W; Irvine RA; Yu MC; Ross RK; Coetzee GA; Ingles SA
Cancer Res; 2000 Feb; 60(4):839-41. PubMed ID: 10706090
[TBL] [Abstract][Full Text] [Related]
7. Androgen receptor mutations and polymorphisms in African American prostate cancer.
Koochekpour S; Buckles E; Shourideh M; Hu S; Chandra D; Zabaleta J; Attwood K
Int J Biol Sci; 2014; 10(6):643-51. PubMed ID: 24948877
[TBL] [Abstract][Full Text] [Related]
8. Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk.
Sun J; Wiklund F; Zheng SL; Chang B; Bälter K; Li L; Johansson JE; Li G; Adami HO; Liu W; Tolin A; Turner AR; Meyers DA; Isaacs WB; Xu J; Grönberg H
J Natl Cancer Inst; 2005 Apr; 97(7):525-32. PubMed ID: 15812078
[TBL] [Abstract][Full Text] [Related]
9. Difference between Swedish and Japanese men in the association between AR CAG repeats and prostate cancer suggesting a susceptibility-modifying locus overlapping the androgen receptor gene.
Li C; Grönberg H; Matsuyama H; Weber G; Nordenskjöld M; Naito K; Bergh A; Bergerheim U; Damber JE; Larsson C; Ekman P
Int J Mol Med; 2003 Apr; 11(4):529-33. PubMed ID: 12632109
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor polymorphism-dependent variation in prostate-specific antigen concentrations of European men.
Bentmar Holgersson M; Giwercman A; ; Bjartell A; Wu FC; Huhtaniemi IT; O'Neill TW; Pendleton N; Vanderschueren D; Lean ME; Han TS; Finn JD; Kula K; Forti G; Casanueva FF; Bartfai G; Punab M; ; Lundberg Giwercman Y
Cancer Epidemiol Biomarkers Prev; 2014 Oct; 23(10):2048-56. PubMed ID: 25012998
[TBL] [Abstract][Full Text] [Related]
11. PSA and androgen-related gene (AR, CYP17, and CYP19) polymorphisms and the risk of adenocarcinoma at prostate biopsy.
dos Santos RM; de Jesus CM; Trindade Filho JC; Trindade JC; de Camargo JL; Rainho CA; Rogatto SR
DNA Cell Biol; 2008 Sep; 27(9):497-503. PubMed ID: 18491956
[TBL] [Abstract][Full Text] [Related]
12. Genetic determinants of serum prostate-specific antigen levels in healthy men from a multiethnic cohort.
Xue WM; Coetzee GA; Ross RK; Irvine R; Kolonel L; Henderson BE; Ingles SA
Cancer Epidemiol Biomarkers Prev; 2001 Jun; 10(6):575-9. PubMed ID: 11401905
[TBL] [Abstract][Full Text] [Related]
13. Significance of the CAG repeat polymorphism of the androgen receptor gene in prostate cancer progression.
Nam RK; Elhaji Y; Krahn MD; Hakimi J; Ho M; Chu W; Sweet J; Trachtenberg J; Jewett MA; Narod SA
J Urol; 2000 Aug; 164(2):567-72. PubMed ID: 10893645
[TBL] [Abstract][Full Text] [Related]
14. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era.
Platz EA; Leitzmann MF; Rifai N; Kantoff PW; Chen YC; Stampfer MJ; Willett WC; Giovannucci E
Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1262-9. PubMed ID: 15894683
[TBL] [Abstract][Full Text] [Related]
15. Association of androgen receptor, prostate-specific antigen, and CYP19 gene polymorphisms with prostate carcinoma and benign prostatic hyperplasia in a north Indian population.
Soni A; Bansal A; Mishra AK; Batra J; Singh LC; Chakraborty A; Yadav DS; Mohanty NK; Saxena S
Genet Test Mol Biomarkers; 2012 Aug; 16(8):835-40. PubMed ID: 22731640
[TBL] [Abstract][Full Text] [Related]
16. Variants in the prostate-specific antigen (PSA) gene and prostate cancer risk, survival, and circulating PSA.
Severi G; Hayes VM; Neufing P; Padilla EJ; Tilley WD; Eggleton SA; Morris HA; English DR; Southey MC; Hopper JL; Sutherland RL; Boyle P; Giles GG
Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1142-7. PubMed ID: 16775173
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive assessment of candidate genes and serological markers for the detection of prostate cancer.
Nam RK; Zhang WW; Trachtenberg J; Jewett MA; Emami M; Vesprini D; Chu W; Ho M; Sweet J; Evans A; Toi A; Pollak M; Narod SA
Cancer Epidemiol Biomarkers Prev; 2003 Dec; 12(12):1429-37. PubMed ID: 14693733
[TBL] [Abstract][Full Text] [Related]
18. CCR2 and CCR5 genes polymorphisms in benign prostatic hyperplasia and prostate cancer.
Zambra FM; Biolchi V; Brum IS; Chies JA
Hum Immunol; 2013 Aug; 74(8):1003-8. PubMed ID: 23632061
[TBL] [Abstract][Full Text] [Related]
19. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.
Yli-Hemminki TH; Laurila M; Auvinen A; Määttänen L; Huhtala H; Tammela TL; Kujala PM
BJU Int; 2013 Oct; 112(6):735-41. PubMed ID: 23746332
[TBL] [Abstract][Full Text] [Related]
20. Effects of prostate-specific antigen testing on familial prostate cancer risk estimates.
Bratt O; Garmo H; Adolfsson J; Bill-Axelson A; Holmberg L; Lambe M; Stattin P
J Natl Cancer Inst; 2010 Sep; 102(17):1336-43. PubMed ID: 20724726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
